Latest Information Update: 06 Jun 2002
At a glance
- Originator Roche
- Mechanism of Action Serotonin 2B receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Migraine
Most Recent Events
- 06 Jun 2002 Discontinued - Phase-I for Migraine in USA (unspecified route)
- 23 May 2000 New profile
- 23 May 2000 Phase-I clinical trials for Migraine in USA (Unknown route)